Singapore Exchange took part in a Hillhouse Capital-led round that the electronic trading platform will use to expand its corporate bond business in the US.

Dell Technologies Capital, BMW i Ventures and GE Ventures returned to back on-demand manufacturing platform Xometry, increasing its overall funding haul to $113m.

JSR and SymBiosis took part in an $18.5m series C extension for PureTech spinoff Vedanta, growing the Bristol-Myers Squibb and PureTech Health-backed round to $45.5m.

The series A, led by corporate venturing unit GV, may not have been last week’s largest deal, but Verve’s tie-up with fellow Harvard spinout Beam Therapeutics tells an intriguing story.

The Posco-backed pulmonary device maker has collected $65m in an oversubscribed round led by Ally Bridge Group, taking its equity funding to $135m to date.

Hanwha Asset Management contributed to a round that boosted the online life insurance provider's overall funding to about $140m.

Johnson & Johnson, Novartis and Astellas all took part in the first close of a round for oncology therapy developer 28-7 Therapeutics that now stands at $82.8m.

OUP and Sofinnova Partners invested in 28-7 Therapeutics to take its series A round to $82.8m, enabling the Harvard spinout to pursue accelerated development of its cancer drug pipeline.

GV led a $58.5m round for the heart disease drug developer, which is advancing research conducted at Harvard University and Broad Institute and has a partnership in place with Harvard spinout Beam Therapeutics.

The financial comparison platform has received a total of $80m to date from investors including Aegon, at least $30m of which was secured in 2019.